oxypurinol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Oxipurinol is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reduces uric acid production. High serum uric acid levels may result in gout, kidney stones, and other medical conditions.   Wikipedia

Chemistry

  • SMILES: O=C1NC(=O)c2c[nH]nc2N1
  • InChIKey: HXNFUBHNUDHIGC-UHFFFAOYSA-N
  • Mol. Mass: 152.11
  • ALogP: -1.06
  • ChEMBL Molecule:
    oxypurinol  
More Chemistry

Pharmacology

Alternative names

1h-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione | 1h-pyrazolo[3,4-d]pyrimidine-4,6-diol | 6-hydroxy allopurinol | 7,7',8,8'-tetrahydro-beta,beta-carotene-3,3'-diolbeta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)- | alloxanthin | alloxanthine | beta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)- | dhpp | metabolite of allopurinol | oxipurinol | oxipurinolum | oxoallopurinol | oxyprim | oxypurinol

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Anemia, Sickle Cell (Phase 1)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue